Literature DB >> 22659976

Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.

Hugo A Tejeda1, Luis A Natividad, James E Orfila, Oscar V Torres, Laura E O'Dell.   

Abstract

RATIONALE: Mechanisms that mediate age differences during nicotine withdrawal are unclear.
OBJECTIVE: This study compared kappa-opioid receptor (KOR) activation in naïve and nicotine-treated adolescent and adult rats using behavioral and neurochemical approaches to study withdrawal.
METHODS: The behavioral models used to assess withdrawal included conditioned place and elevated plus maze procedures. Deficits in dopamine transmission in the nucleus accumbens (NAcc) were examined using microdialysis procedures. Lastly, the effects of KOR stimulation and blockade on physical signs produced upon removal of nicotine were examined in adults.
RESULTS: Nicotine-treated adults displayed a robust aversion to an environment paired with a KOR agonist versus naïve adults. Neither of the adolescent groups displayed a place aversion. KOR activation produced an increase in anxiety-like behavior that was highest in nicotine-treated adults versus all other groups. KOR activation produced a decrease in NAcc dopamine that was largest in nicotine-treated adults versus all other groups. Lastly, KOR activation facilitated physical signs of withdrawal upon removal of nicotine and KOR blockade reduced this effect.
CONCLUSION: Chronic nicotine enhanced the affective, anxiogenic, and neurochemical effects produced by KOR activation in adult rats. Our data suggest that chronic nicotine elicits an increase in KOR function, and this may contribute to nicotine withdrawal since KOR activation facilitated and KOR blockade prevented withdrawal signs upon removal of nicotine. Given that chronic nicotine facilitated the neurochemical effects of KOR agonists in adults but not in adolescents, it is suggested that KOR regulation of mesolimbic dopamine may contribute to age differences in nicotine withdrawal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659976      PMCID: PMC3482308          DOI: 10.1007/s00213-012-2752-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal.

Authors:  Gökhan Göktalay; Sinan Cavun; Mark C Levendusky; Jonathan R Hamilton; William R Millington
Journal:  Eur J Pharmacol       Date:  2005-12-20       Impact factor: 4.432

3.  Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects.

Authors:  S S Watkins; L Stinus; G F Koob; A Markou
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

Review 4.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

Review 5.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

6.  Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.

Authors:  A C Thompson; A Zapata; J B Justice; R A Vaughan; L G Sharpe; T S Shippenberg
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

7.  Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats.

Authors:  R Bals-Kubik; A Ableitner; A Herz; T S Shippenberg
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

8.  Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.

Authors:  T S Shippenberg; R Bals-Kubik; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Nicotine dependence and reward differ between adolescent and adult male mice.

Authors:  D Kota; B R Martin; S E Robinson; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2007-04-19       Impact factor: 4.030

10.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  25 in total

1.  Cholinergic transmission during nicotine withdrawal is influenced by age and pre-exposure to nicotine: implications for teenage smoking.

Authors:  Luis M Carcoba; James E Orfila; Luis A Natividad; Oscar V Torres; Joseph A Pipkin; Patrick L Ferree; Eddie Castañeda; Donald E Moss; Laura E O'Dell
Journal:  Dev Neurosci       Date:  2014-05-15       Impact factor: 2.984

2.  Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

Authors:  Kia J Jackson; Asti Jackson; F Ivy Carroll; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

Review 3.  Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders.

Authors:  Smita Das; Judith J Prochaska
Journal:  Expert Rev Respir Med       Date:  2017-08-09       Impact factor: 3.772

Review 4.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

5.  Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.

Authors:  Rosemarie A Martin; Damaris J Rohsenow; Jennifer W Tidey
Journal:  J Subst Abuse Treat       Date:  2019-06-10

6.  Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.

Authors:  Chloe M Erikson; Gengze Wei; Brendan M Walker
Journal:  Neuropharmacology       Date:  2018-07-31       Impact factor: 5.250

7.  Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal.

Authors:  Luis A Natividad; Matthew W Buczynski; Loren H Parsons; Oscar V Torres; Laura E O'Dell
Journal:  J Neurochem       Date:  2012-10-01       Impact factor: 5.372

8.  A mechanistic hypothesis of the factors that enhance vulnerability to nicotine use in females.

Authors:  Laura E O'Dell; Oscar V Torres
Journal:  Neuropharmacology       Date:  2013-05-17       Impact factor: 5.250

Review 9.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

10.  Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats.

Authors:  Rachel I Anderson; Melissa Morales; Linda P Spear; Elena I Varlinskaya
Journal:  Psychopharmacology (Berl)       Date:  2013-04-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.